Vitality Watch

Dossier pubmed review 17-jul-2026
Narrative review or expert overview without new data

Palmitoylation in cardiovascular aging and disease: Mechanistic insights and therapeutic opportunities.

Key claim: Dysregulated protein palmitoylation under metabolic stress contributes to cardiovascular aging by promoting mitochondrial dysfunction, impaired autophagy, oxidative stress, and cellular senescence, creating a palmitoylation-driven metabolic vicious cycle that may be therapeutically targetable.

Abstract

Cardiovascular aging is a major contributor to the development of cardiovascular diseases (CVDs), yet the mechanisms linking metabolic imbalance to age-related cardiovascular dysfunction remain unclear. Protein palmitoylation, a reversible lipid post-translational modification, regulates protein localization, stability, and signaling, but its role in cardiovascular aging has not been systematically defined. Importantly, protein palmitoylation appears to act as a double-edged sword: whereas its physiological regulation is indispensable for cardiovascular homeostasis, aberrant palmitoylation under metabolic stress may drive aging and disease progression. In this review, we summarize current evidence indicating that dysregulated palmitoylation contributes to key features of cardiovascular aging, including mitochondrial dysfunction, impaired autophagy, oxidative stress, and cellular senescence. We further integrate findings across cardiomyocytes, endothelial cells, fibroblasts, and immune cells to highlight the role of palmitoylation in coordinating cellular dysfunction and intercellular communication during cardiovascular aging and disease. We propose a “palmitoylation-driven metabolic vicious cycle” that links metabolic disorders to enhanced palmitoylation and progressive cardiovascular injury. In addition, we discuss emerging detection approaches and therapeutic strategies targeting palmitoylation. Overall, this review provides a mechanistic framework linking palmitoylation to cardiovascular aging and disease and identifies potential targets for intervention in aging-related CVDs.

Why this matters

Palmitoylation is a reversible lipid post-translational modification, which makes it attractive as a druggable node — but here it is being positioned as an integrative upstream driver that ties mitochondrial dysfunction, autophagy failure, oxidative stress, and senescence into a single cardiovascular-aging vicious cycle. That framing consolidates several separately-tracked hallmark mechanisms under one enzymatic axis (DHHC-PATs / APT-thioesterases), which will matter if selective palmitoylation modulators enter the geroscience pipeline; the current evidence base is preclinical and pathway-level, and no human cardiovascular-aging endpoint has been tied to a palmitoylation-targeted intervention.

Source

Link

Briefing card

Palmitoylation in cardiovascular aging and disease: Mechanistic insights and therapeutic opportunities.
Stage: review · pubmed · 17-jul-2026

Dysregulated protein palmitoylation under metabolic stress contributes to cardiovascular aging by promoting mitochondrial dysfunction, impaired autophagy, oxidative stress, and cellular senescence, creating a palmitoylation-driven metabolic vicious cycle that may be therapeutically targetable.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.arr.2026.103261

build build 880 · 2bcef25 · 2026-11-18